Scarica l'app Stockscreener
11.61
2.20%
0.25
Pre-mercato:
11.99
0.38
+3.27%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché NVCR Giù?
Forum
Previsione
Novocure Ltd Borsa (NVCR) Ultime notizie
Novocure stock rises on positive pancreatic cancer trial data By Investing.com - Investing.com South Africa
PANOVA-4 Phase 2 trial shows promising TTFields therapy results, NovoCure Ltd reveals - Traders Union
Novocure (NASDAQ: NVCR) reports positive PANOVA-4 pancreatic cancer data - Stock Titan
Pancreatic cancer trial posts 74.4% disease control with Novocure - Stock Titan
Tudor Investment Corp ET AL Purchases 354,216 Shares of NovoCure Limited $NVCR - MarketBeat
NovoCure Limited $NVCR Position Lifted by Algert Global LLC - MarketBeat
Capital World Investors Lowers Holdings in NovoCure Limited $NVCR - MarketBeat
FDA Approves Novocure’s Optune Pax Wearable Device for Pancreatic Cancer - Digital Health News
NovoCure Limited $NVCR Shares Acquired by American Century Companies Inc. - MarketBeat
Novocure at Leerink Conference: Strategic Growth in Cancer Treatment By Investing.com - Investing.com South Africa
Novocure at Leerink Conference: Strategic Growth in Cancer Treatment - Investing.com Australia
Should Japan’s Optune Lua Reimbursement Win Reframe NovoCure’s (NVCR) Access and Utilization Story? - Sahm
Novocure's Optune Lua Gets Japan Reimbursement for NSCLC Treatment - Yahoo Finance
Assessing Novocure (NVCR) Valuation After Japan Reimbursement Approval For Optune Lua - Sahm
NovoCure Limited (NASDAQ:NVCR) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
Insider Selling: NovoCure (NASDAQ:NVCR) Insider Sells 1,100 Shares of Stock - MarketBeat
NovoCure (NASDAQ:NVCR) CFO Sells $85,343.72 in Stock - MarketBeat
NovoCure (NASDAQ:NVCR) CEO Sells $74,629.17 in Stock - MarketBeat
Mukund Paravasthu Sells 5,377 Shares of NovoCure (NASDAQ:NVCR) Stock - MarketBeat
NovoCure (NASDAQ:NVCR) COO Mukund Paravasthu Sells 43,246 Shares - MarketBeat
NVCR Crosses Above Key Moving Average Level - Nasdaq
NovoCure (NVCR) General Counsel receives new stock options and RSU grants - Stock Titan
NovoCure (NASDAQ: NVCR) CMO reports tax sale and new stock awards - Stock Titan
[144] NovoCure Ltd SEC Filing - Stock Titan
NVCR (NASDAQ) Form 144: Insider-related sales include 3,272 and 7,461 shares - Stock Titan
NovoCure Ltd. Hits Day Low of $11.80 Amid Price Pressure - Markets Mojo
Vanguard Group Inc. Sells 296,555 Shares of NovoCure Limited $NVCR - MarketBeat
NovoCure Limited $NVCR Shares Bought by Quantbot Technologies LP - MarketBeat
NovoCure (NVCR) CMO sells shares to cover RSU tax withholding - Stock Titan
NovoCure (NVCR) CHRO sells 1,441 shares in tax withholding trade - Stock Titan
NovoCure (NVCR) COO offloads 1,963 shares in tax sell-to-cover - Stock Titan
Tax-withholding sale of 1,029 NovoCure (NASDAQ: NVCR) shares by ex-CMO - Stock Titan
NovoCure (NVCR) CEO reports RSU vesting and tax-cover share sales - Stock Titan
Equity awards and tax share withholding for NovoCure (NVCR) ex-CEO Cordova - Stock Titan
NovoCure (NASDAQ: NVCR) General Counsel receives 17,755-share performance award - Stock Titan
NovoCure (NVCR) Is Up 24.5% After FDA Approval Of Optune Pax And 2026 Guidance Update - Sahm
Novocure gains Japan reimbursement for Optune Lua device - Investing.com Australia
NovoCure Limited 2025 Q4ResultsEarnings Call Presentation (NASDAQ:NVCR) 2026-03-02 - Seeking Alpha
NovoCure Ltd wins Japanese reimbursement approval for lung cancer treatment - Traders Union
NovoCure (NVCR) Reliance on International Sales: What Investors Need to Know - Yahoo Finance
Novocure (NVCR) Gains Japanese Reimbursement Approval for Optune Lua - GuruFocus
Novocure (NVCR) Gains Approval for Optune Lua Reimbursement in J - GuruFocus
Novocure gains Japan reimbursement for Optune Lua device By Investing.com - Investing.com Canada
Japan’s health system to cover wearable lung cancer device Optune Lua - Stock Titan
NovoCure Earnings Call: Growth Builds Amid Profit Strain - The Globe and Mail
Equities Analysts Set Expectations for NovoCure Q1 Earnings - MarketBeat
A Look At NovoCure (NVCR) Valuation As Record 2025 Results And Optune Pax Approval Reset Growth Expectations - Yahoo Finance
NovoCure Ltd. Opens with 6.47% Gain, Outpacing S&P 500's 0.69% Rise - Markets Mojo
NovoCure Shares Gap Down, Weak Start Raises Market Concerns - Markets Mojo
NovoCure Ltd. Hits Day High with 27.68% Surge in Stock Price - Markets Mojo
NovoCure Ltd. Experiences Revision in Stock Evaluation Amidst Market Challenges - Markets Mojo
Is NovoCure (NVCR) Pricing Look Out Of Step With Recent Share Rebound - simplywall.st
NovoCure’s Pancreatic Cancer Approval And New CEO Shift Risk Reward Profile - simplywall.st
1.53%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):